In 2024, Patrick Malone, a physician-turned-investor at KdT Ventures, recognized a significant shift in the global biopharma landscape when he discovered that Chinese companies had surged to dominate pharmaceutical licensing deals. In 2022, 23% of large global deals involved Chinese firms, which skyrocketed to 44% by 2024. Tim Opler from Stifel Institutional echoed this concern, noting that by 2025, nearly 70% of the financial resources in pharmaceutical deals—amounting to $137.7 billion—were directed towards Chinese start-ups. Both Malone and Opler highlighted the unprecedented pace at which China is reshaping the biopharma sector, raising alarms about its growing influence in the industry.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.thefp.com/p/china-biotech-pharmaceutical-development
